Navigation Links
VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
Date:8/23/2011

om the company by contacting VIVUS, Inc., Attention: Corporate Secretary, 1172 Castro Street, Mountain View, CA 94040, (650) 934-5200.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the timing and substance of our response to the FDA's requests from the End of Review meeting; our response to, and continued dialogue with, the FDA relating to matters raised in the FDA's CRL; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy or FORTRESS; the FDA's interpretation of and agreement with the information VIVUS submitted and may submit relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SE
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
2. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
3. VIVUS to Present at Three Upcoming Investor Conferences in March
4. VIVUS Provides Regulatory Update on QNEXA NDA
5. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
6. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
7. VIVUS to Present at Two Upcoming Investor Conferences
8. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
9. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
10. VIVUS Announces Sale of MUSE Assets to Meda
11. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 Mallinckrodt plc (NYSE: ... announced that it has completed its acquisition of ... $2.3 billion. The Ikaria acquisition extends Mallinckrodt,s footprint ... into neonatal critical care with INOMAX ® ... a highly vulnerable patient population. It also accelerates ...
(Date:4/16/2015)... , April 16, 2015  Diplomat Pharmacy, Inc. ... Shannon Beltrand to their senior leadership team as ... be responsible for securing and properly monitoring Diplomat,s data, ... both internally and externally. Additionally, she will play key ... "We are very excited to have someone ...
(Date:4/16/2015)... YORK , April 16, 2015 An ... additional way to generate trimers from the major HIV ... could benefit future clinical development of HIV vaccine candidates ... the critical target on the surface of HIV for ... an important platform for AIDS vaccine discovery, says ...
Breaking Medicine Technology:Mallinckrodt Completes Acquisition Of Ikaria 2Mallinckrodt Completes Acquisition Of Ikaria 3Mallinckrodt Completes Acquisition Of Ikaria 4Mallinckrodt Completes Acquisition Of Ikaria 5Diplomat Names Shannon M. Beltrand as New CISO 2New Method Holds Promise for HIV Vaccine Development 2
(Date:4/17/2015)... Rapids, MI (PRWEB) April 17, 2015 Enthusiasts ... CRUSH Grand Rapids, Saturday, April 25, 2015. The event will ... Reserve Wine & Food (201 Monroe Ave NW, Grand Rapids, ... from around the West Michigan area. Patrons are encouraged to ... of elegance and fun. , This year’s event will feature ...
(Date:4/17/2015)... York (PRWEB) April 17, 2015 ... allege this class of prescription medications increases the ... attack, stroke or other life-threatening cardiovascular event continue ... U.S. District Court, Northern District of Illinois. According ... U.S. Judicial Panel on Multidistrict Litigation (JPML) on ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 The American College of ... and Free Application Day on April 29. The event will be ... Square, located at 555 DeHaro St. in San Francisco, CA. , ... – Check in at the DeHaro campus (room F), 11:10 a.m. ... of campus, Noon – Light lunch with current students, faculty and ...
(Date:4/17/2015)... Carolina (PRWEB) April 17, 2015 With ... Dental Care has spent the last four years ... care, performing procedures ranging from general cleanings to dental ... a grand opening at their new office in North ... same services as their Concord office, including denture fittings, ...
(Date:4/17/2015)... April 17, 2015 Mario ... polish and perfect facial skin with its unique ... and blend of energizing botanicals. This cushiony gel-based ... that cause breakouts and inhibit penetration of special ... Ecuadorian Ivory Palm Seeds, This uncommon exfoliating ingredient ...
Breaking Medicine News(10 mins):Health News:Children’s Leukemia Foundation of Michigan Presents 3rd Annual CRUSH Grand Rapids 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 3Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 4Health News:American College of Traditional Chinese Medicine Hosts Open House 2Health News:Mario Badescu Skin Care Launches Botanical Exfoliating Scrub 2
... weight loss and preventive cardiology. The unique medical practice will offer ... pantry makeovers. , ... Denver, CO (PRWEB) August 10, ... change the way the medical community treats obesity by improving patients, ...
... Cryoablation attractive option for older patients with other medical ... News) -- A new method of freezing damaged cells ... is being used by gastroenterologists at the University of ... condition called Barrett,s esophagus can result from ongoing heartburn, ...
... selected iCRco, an American CR Company, as its new Digital Imaging ... diagnoses for our troops injured in battle. , ... ... an American CR Company, as its new Digital Imaging provider. iCRco,s ...
... Investor Conference Call on Monday, August 11, 2008 at 8:30am ... ... 8 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopharmaceutical company focused ... treatment of life-threatening,diseases, including renal disease and cancer, today announced its results,for ...
... Inc., administrator for the,HealthShares(TM) Indexes, a series ... Traded Funds, today announced the following changes,effective ... August 11, 2008: Enzo Biochem,Inc. will replace ... the,HealthShares(TM) Infectious Disease Index and the HealthShares(TM),Composite ...
... MedQuist,Inc.,(Nasdaq: MEDQ ) the largest Medical Transcription Service ... the quarter ended June,30, 2008. Revenue for the second ... in the second quarter of 2007. The decrease in ... period was primarily due to,customer losses experienced during the ...
Cached Medicine News:Health News:Weight Loss and Disease Prevention Head Home 2Health News:New Therapy Freezes Out Esophageal Cancers 2Health News:US Military Chooses American Made iCRco Digital Radiography Systems 2Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 2Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 3Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 4Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 5Health News:Mergent, Inc. Announces Changes to the HealthShares(TM) Infectious Disease and HealthShares(TM) Composite Indexes 2Health News:MedQuist Reports Second Quarter 2008 Results 2Health News:MedQuist Reports Second Quarter 2008 Results 3Health News:MedQuist Reports Second Quarter 2008 Results 4Health News:MedQuist Reports Second Quarter 2008 Results 5Health News:MedQuist Reports Second Quarter 2008 Results 6Health News:MedQuist Reports Second Quarter 2008 Results 7Health News:MedQuist Reports Second Quarter 2008 Results 8Health News:MedQuist Reports Second Quarter 2008 Results 9
Visionary OFFICE™ PM offers a Windows interface featuring medical billing, appointment scheduling and patient information....
... Medical Billing system allows a practice ... It is integrated with the EMR, ... system interfaces with electronic clearinghouses for ... a set of reports, it presents ...
... The Infinity Amylase CPNG3 single ... all the convenience of single liquid ... minimize operator error and provide quick ... of the Infinity Amylase CPNG3 reagent ...
... Infinity Uric Acid single liquid stable ... convenience of single liquid stability to ... error and provide quick result turnaround ... Infinity Uric Acid reagent provides a ...
Medicine Products: